Clinical Trial Update: Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

This document notes the termination of a Phase 1 clinical trial evaluating donor-derived CD5 CAR T cells for relapsed or refractory T-cell acute lymphoblastic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Donor-Derived CD5 CAR T Cells (CD5 CAR T cell therapy)

Snippet

Sponsor: Beijing Boren Hospital | Conditions: T-Cell Acute Lymphoblastic Leukemia | Phase 1 | Status: TERMINATED